Canada Markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
253.65-1.23 (-0.48%)
At close: 04:00PM EST
255.34 +1.69 (+0.67%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close254.88
Open254.87
Bid253.66 x 1000
Ask255.34 x 800
Day's Range252.54 - 255.50
52 Week Range214.39 - 296.67
Volume2,109,859
Avg. Volume2,661,286
Market Cap142.872B
Beta (5Y Monthly)0.58
PE Ratio (TTM)21.01
EPS (TTM)12.07
Earnings DateFeb 06, 2023 - Feb 10, 2023
Forward Dividend & Yield7.76 (2.98%)
Ex-Dividend DateAug 17, 2022
1y Target Est254.85
  • Zacks

    Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know

    Amgen (AMGN) closed the most recent trading day at $254.88, moving -0.65% from the previous trading session.

  • Reuters

    UPDATE 2-U.S. Senator Warren 'particularly concerned' about Amgen, Indivior deals

    Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals. In a letter dated Wednesday, Warren said that she was focused on Amgen's plan to buy Horizon Therapeutics , and addiction specialist Indivior's plan to buy Opiant for $145 million, which was announced in mid-November. "Given these companies' records of anti-competitive business practices, these acquisitions could cause further price increases on lifesaving drugs and prevent affordable alternatives from entering the market," she wrote in the letter to FTC Chair Lina Khan as well as Commissioners Rebecca Slaughter and Alvaro Bedoya, all of whom are Democrats.

  • Reuters

    U.S. Senator Warren 'particularly concerned' about Amgen, Indivior deals

    WASHINGTON (Reuters) -Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals. In a letter dated Wednesday, Warren said that she was focused on Amgen's plan to buy Horizon Therapeutics, and addiction specialist Indivior's plan to buy Opiant for $145 million, which was announced in mid-November.